[go: up one dir, main page]

WO2016167605A3 - Procédé pour inhiber le cancer du poumon chez des fumeurs et des non-fumeurs au moyen d'un médicament contre l'hypertension - Google Patents

Procédé pour inhiber le cancer du poumon chez des fumeurs et des non-fumeurs au moyen d'un médicament contre l'hypertension Download PDF

Info

Publication number
WO2016167605A3
WO2016167605A3 PCT/KR2016/003957 KR2016003957W WO2016167605A3 WO 2016167605 A3 WO2016167605 A3 WO 2016167605A3 KR 2016003957 W KR2016003957 W KR 2016003957W WO 2016167605 A3 WO2016167605 A3 WO 2016167605A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
smokers
hypertension medicine
present
clinical application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/003957
Other languages
English (en)
Korean (ko)
Other versions
WO2016167605A2 (fr
Inventor
이호영
민혜영
부혜진
장현지
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
Seoul National University R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160045773A external-priority patent/KR101938036B1/ko
Application filed by Seoul National University R&DB Foundation filed Critical Seoul National University R&DB Foundation
Publication of WO2016167605A2 publication Critical patent/WO2016167605A2/fr
Publication of WO2016167605A3 publication Critical patent/WO2016167605A3/fr
Priority to US15/784,538 priority Critical patent/US11123335B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant d'inhiber le cancer du poumon chez des fumeurs et des non-fumeurs, par blocage de la signalisation de facteurs de croissance, en utilisant un médicament contre l'hypertension, et plus spécifiquement une composition pharmaceutique pour prévenir ou traiter le cancer du poumon, contenant un médicament contre l'hypertension en tant que principe actif. La présente invention porte sur une nouvelle utilisation d'un médicament contre l'hypertension, en d'utilisation clinique, pour prévenir le cancer du poumon, qui peut être directement appliqué à un groupe à haut risque d'être atteint d'un cancer du poumon ou atteint d'un cancer du poumon à un stade précoce. En particulier, la présente invention permet d'exclure le souci de sécurité, impliqué dans l'application clinique de nouveaux médicaments, ce qui permet d'augmenter la possibilité de l'application clinique et de réduire significativement les coûts et le temps conséquents déployés depuis la mise au point jusqu'à l'application clinique de nouveaux médicaments.
PCT/KR2016/003957 2015-04-16 2016-04-15 Procédé pour inhiber le cancer du poumon chez des fumeurs et des non-fumeurs au moyen d'un médicament contre l'hypertension Ceased WO2016167605A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/784,538 US11123335B2 (en) 2015-04-16 2017-10-16 Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2015-0053921 2015-04-16
KR20150053921 2015-04-16
KR10-2016-0045773 2016-04-14
KR1020160045773A KR101938036B1 (ko) 2015-04-16 2016-04-14 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/784,538 Continuation-In-Part US11123335B2 (en) 2015-04-16 2017-10-16 Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug

Publications (2)

Publication Number Publication Date
WO2016167605A2 WO2016167605A2 (fr) 2016-10-20
WO2016167605A3 true WO2016167605A3 (fr) 2016-12-29

Family

ID=57126215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003957 Ceased WO2016167605A2 (fr) 2015-04-16 2016-04-15 Procédé pour inhiber le cancer du poumon chez des fumeurs et des non-fumeurs au moyen d'un médicament contre l'hypertension

Country Status (1)

Country Link
WO (1) WO2016167605A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102217010B1 (ko) * 2018-01-26 2021-02-18 재단법인 대구경북첨단의료산업진흥재단 칼슘 채널 억제제 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN111825599A (zh) * 2019-04-17 2020-10-27 上海中医药大学附属龙华医院 新型Neddylation抑制剂的医药用途
CN114621959B (zh) * 2020-12-08 2023-05-26 中国科学院海洋研究所 一种编码牙鲆igf2可溶性蛋白的基因及蛋白重组表达方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
WO2012071573A2 (fr) * 2010-11-24 2012-05-31 Mount Sinai School Of Medicine Matériaux et procédés pour la prévention et le traitement du cancer
WO2014018563A2 (fr) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour le traitement du cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
WO2012071573A2 (fr) * 2010-11-24 2012-05-31 Mount Sinai School Of Medicine Matériaux et procédés pour la prévention et le traitement du cancer
WO2014018563A2 (fr) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour le traitement du cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI, J. ET AL.: "Telmisartsn Exerts Anti-tumor Effects by Activating Peroxisome Proliferator-activated Receptor-y in Human Lung Adenocarcinoma A549 Cells", MOLECULES, vol. 19, no. 3, 5 March 2014 (2014-03-05), pages 2862 - 2876, XP055340534 *
SCHULLER, H. M.: "Effects of Tobacco Constituents and Psychological Stress on the Beta-adrenergic Regulation of Non-small Cell Lung Cancer and Pancreatic Cancer: Implications for Intervention", CANCER BIOMARKERS, vol. 13, no. 3, 1 January 2013 (2013-01-01), pages 133 - 144 *
YASUMARU, M. ET AL.: "Inhibition of Angiotensin II Activity Enhanced the Antitumor Effect of Cyclooxygenase-2 Inhibitors via Insulin-like Growth Factor I Receptor Pathway", CANCER RESEARCH, vol. 63, no. 20, 15 October 2003 (2003-10-15), pages 6726 - 6734, XP055340535 *

Also Published As

Publication number Publication date
WO2016167605A2 (fr) 2016-10-20

Similar Documents

Publication Publication Date Title
PH12019501685A1 (en) Quinazone compound
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY198339A (en) Mono-Or Di-Substituted Indole Derivatives as Dengue Viral Replication Inhibitors
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
WO2016046260A8 (fr) Composés de 1-alkyl-6-oxo-1,6-dihydropyridin-3-yle et leur utilisation comme modulateurs sgrm
MY194711A (en) Novel annelated phenoxyacetamides
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2016167605A3 (fr) Procédé pour inhiber le cancer du poumon chez des fumeurs et des non-fumeurs au moyen d'un médicament contre l'hypertension
MY205197A (en) Methyllactam ring compound and pharmaceutical use thereof
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
MX2018002575A (es) Compuesto y sal del mismo que tiene efecto de inhibir la agregacion plaquetaria y composicion para prevenir o tratar enfermedades tromboticas que lo contienen.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16780328

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16780328

Country of ref document: EP

Kind code of ref document: A2